Dr. Phillips on Activity With Acalabrutinib Plus Bendamustine/Rituximab in MCL
December 2nd 2018
Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses safety and efficacy findings for acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed/refractory mantle cell lymphoma (MCL) during the 2018 ASH Annual Meeting.